Early research (Phase 1)Study completedNCT02262910What this trial is testingStudy of ES414 in Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate Cancer Aptevo Therapeutics 35
Early research (Phase 1)Study completedNCT00327288What this trial is testingSafety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer PatientsWho this might be right forNon-small Cell Lung CancerBreast CancerProstate Cancer AmpliMed Corporation 34
Not applicableApproved For MarketingNCT01606982What this trial is testingProvide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyWho this might be right forMetastatic Castration-Resistant Prostate Cancer Astellas Pharma Global Development, Inc.
Not applicableWithdrawnNCT03596710What this trial is testingImage-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand TherapyWho this might be right forCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer Jonsson Comprehensive Cancer Center
Not applicableStudy completedNCT03329742What this trial is testingSipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate CancerWho this might be right forProstate Cancer Recurrent Indiana University 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT04253262What this trial is testingCopanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer Brown University 13
Testing effectiveness (Phase 2)Looking for participantsNCT06970119What this trial is testingA Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate CancerWho this might be right forProstate Cancer Yunhe Pharmaceutical (Tianjin) Co., Ltd 55
Early research (Phase 1)Looking for participantsNCT05613894What this trial is testingDose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer University of Utah 33
Testing effectiveness (Phase 2)Study completedNCT01240629What this trial is testingDoxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate CancerWho this might be right forProstate CancerHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more University of Southern California 43
Testing effectiveness (Phase 2)Looking for participantsNCT06457919What this trial is testingTinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate CancerWho this might be right forProstate Cancer Memorial Sloan Kettering Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT00140400What this trial is testingPrime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate CancerWho this might be right forProstate Cancer Cell Genesys 50
Large-scale testing (Phase 3)Study completedNCT00134056What this trial is testingS0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone TherapyWho this might be right forMetastatic CancerProstate Cancer SWOG Cancer Research Network 1,038
Post-approval studies (Phase 4)Study completedNCT01977651What this trial is testingEvaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With EnzalutamideWho this might be right forMetastatic Castration-resistant Prostate Cancer (mCRPC) Astellas Pharma Global Development, Inc. 424
Testing effectiveness (Phase 2)Study completedNCT01685983What this trial is testingAbiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate CancerWho this might be right forProstate Cancer Janssen Research & Development, LLC 82
Post-approval studies (Phase 4)Study completedNCT03641560What this trial is testingA Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based ChemotherapyWho this might be right forMetastatic Castration Resistant Prostate Cancer Astellas Pharma Inc 52
Early research (Phase 1)Study completedNCT03569280What this trial is testingEvaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC PatientsWho this might be right forCastration-Resistant Prostate Cancer Kangpu Biopharmaceuticals, Ltd. 16
Not applicableStudy completedNCT04962880What this trial is testingHRR Prevalence in LatAm PROSPECT StudyWho this might be right forCastration-resistant Prostate Cancer AstraZeneca 388
Testing effectiveness (Phase 2)Active Not RecruitingNCT03217747What this trial is testingAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesWho this might be right forAdvanced Malignant Solid NeoplasmCastration-Resistant Prostate CarcinomaMalignant Solid Neoplasm+7 more M.D. Anderson Cancer Center 173
Large-scale testing (Phase 3)Looking for participantsNCT06470243What this trial is testingTesting Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyWho this might be right forCastration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8 SWOG Cancer Research Network 528
Testing effectiveness (Phase 2)Ended earlyNCT04616547What this trial is testingTreatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to BonesWho this might be right forCastration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Prostate Adenocarcinoma+3 more National Cancer Institute (NCI) 1